By identifying genes that are differentially expressed in carriers of BRCA1 and BRCA2 mutations, researchers in Israel are working on developing a test that, if validated, might offer a new approach to gauging people's risk of hereditary breast and ovarian cancer.

Furthermore, since this PCR-based test would gauge the expression of genes other than BRCA1 and BRCA2, the researchers, if they are successful, may have found a true workaround to Myriad Genetics' BRCA gene patents.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.